


GSK Q2 2019 results



GSK delivers sales and earnings growth in Q2 2019

All % at constant exchange rates (CER)



Total Group operating margin
19.0%

Adjusted Group operating margin
27.8%

Total EPS
19.5p
+>100%

Adjusted EPS
30.5p
+4%

Free cash flow
£0.4bn

Dividend
19p

See **press release** on www.gsk.com for full details on Q2 2019.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on page 9 and 62 of the press release.

CER% represents growth at constant exchange rates. For a full explanation please see page 61 of the press release.



Immune system T-cells attacking a cancer cell